Please Scroll Down to See Forums Below 
Seems like every week it is found that marijuana has more benefits...check this out:
Cannabinoids Modulate Epileptic Seizures, Study Says
Richmond, VA: Administration of delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana, "completely abolished" spontaneous seizures in an animal model of epilepsy, according to findings published this week in the Journal of Pharmacology and Experimental Therapeutics. Authors also noted that endogenous cannabinoids, marijuana-like substances produced naturally by the human body, appeared to play a role in regulating seizure duration and frequency.
"These data indicate not only the anticonvulsant activity of
exogenously applied cannabinoids, but also suggest that endogenous cannabinoid ... modulate seizure termination and duration," researchers concluded.
The study is the first to examine the role of marijuana and the
endogenous cannabinoid system in an animal model of epilepsy characterized by spontaneous, recurrent seizures.
Previous animal studies have demonstrated that cannabinoids possess anticonvulsant activity; however, a handful of human trials examining the effects of the cannabinoid cannabidiol (CBD) on epileptic-induced seizures have yielded mixed results. A recent trial in England of cannabis extracts on an in vitro form of epilepsy found that extracts performed more effectively than THC alone in treating symptoms of the disease.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Abstracts of the study are available online at:
http://jpet.aspetjournals.org/cgi/content/abstract/307/1/129.
------------------------------------------------------------------------------------
------------------------------------------------------------------------------------
FDA Grants "Fast Track" Status To Pot-Like Drug For Head Trauma
Iselin, NJ: The US Food and Drug Administration (FDA) will review the efficacy of the synthetic marijuana derivative Dexanabinol for the treatment of Traumatic Brain Injury (TBI) on an accelerated basis, the Pharmos pharmaceutical company announced this week. The FDA grants so-called "fast track" status to drugs intended to treat life-threatening conditions for which no approved therapies exist.
Fast track status allows companies to submit their clinical data to the FDA in stages while trials remain ongoing. Dexanabinol is currently being tested in advanced Phase III clinical trials in the US and Europe. A previous Phase II trial by Pharmos of 67 Israeli patients found that Dexanabinol reduced mortality and eased intracranial pressure in patients suffering from severe head injuries.
A 1999 report by the US National Academy of Sciences' Institute of Medicine (IOM) concluded that marijuana's neuroprotective qualities are the "most prominent" of its potential therapeutic applications.
Cannabinoids Modulate Epileptic Seizures, Study Says
Richmond, VA: Administration of delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana, "completely abolished" spontaneous seizures in an animal model of epilepsy, according to findings published this week in the Journal of Pharmacology and Experimental Therapeutics. Authors also noted that endogenous cannabinoids, marijuana-like substances produced naturally by the human body, appeared to play a role in regulating seizure duration and frequency.
"These data indicate not only the anticonvulsant activity of
exogenously applied cannabinoids, but also suggest that endogenous cannabinoid
The study is the first to examine the role of marijuana and the
endogenous cannabinoid system in an animal model of epilepsy characterized by spontaneous, recurrent seizures.
Previous animal studies have demonstrated that cannabinoids possess anticonvulsant activity; however, a handful of human trials examining the effects of the cannabinoid cannabidiol (CBD) on epileptic-induced seizures have yielded mixed results. A recent trial in England of cannabis extracts on an in vitro form of epilepsy found that extracts performed more effectively than THC alone in treating symptoms of the disease.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Abstracts of the study are available online at:
http://jpet.aspetjournals.org/cgi/content/abstract/307/1/129.
------------------------------------------------------------------------------------
------------------------------------------------------------------------------------
FDA Grants "Fast Track" Status To Pot-Like Drug For Head Trauma
Iselin, NJ: The US Food and Drug Administration (FDA) will review the efficacy of the synthetic marijuana derivative Dexanabinol for the treatment of Traumatic Brain Injury (TBI) on an accelerated basis, the Pharmos pharmaceutical company announced this week. The FDA grants so-called "fast track" status to drugs intended to treat life-threatening conditions for which no approved therapies exist.
Fast track status allows companies to submit their clinical data to the FDA in stages while trials remain ongoing. Dexanabinol is currently being tested in advanced Phase III clinical trials in the US and Europe. A previous Phase II trial by Pharmos of 67 Israeli patients found that Dexanabinol reduced mortality and eased intracranial pressure in patients suffering from severe head injuries.
A 1999 report by the US National Academy of Sciences' Institute of Medicine (IOM) concluded that marijuana's neuroprotective qualities are the "most prominent" of its potential therapeutic applications.
